Registration Number
2123U012787, Article
popup.category
Текст
Title
The effect of complex therapy including vitamin D on the quality of life of patients with chronic hepatitis C combined with chronic pancreatitis (AI translated)
popup.author
Derbak M.
Buchok O.
Boldizhar O.
Bletskan M.
Svistak V.
Дербак Марія Антонівна
Бучок Ольга Володимирівна
Болдіжар Олександр Олександрович
Блецкан Мирослава Михайлівна
Свистак Василина Василівна
Derbak M.
Buchok O.
Boldizhar O.
Bletskan M.
Svistak V.
Derbak Mariya Antonivna
Buchok Olha Volodymyrivna
Boldizhar Oleksandr Oleksandrovych
Bletskan Myroslava Mykhailivna
Svystak Vasylyna Vasylivna
popup.publication
01-01-2023
popup.source_user
Ужгородський національний університет
popup.source
https://dspace.uzhnu.edu.ua/handle/lib/85537
popup.publisher
Укр. акад. наук, Полтав. держ. мед. ун-т.
Description
Chronic hepatitis C (CHC) and chronic pancreatitis (CP) are common, mutually aggravating diseases that are often accompanied by nutrient deficiencies, particularly vitamin D. However, currently existing data on the feasibility of inclusion of vitamin D in the complex therapy of patients with CHC and CP are contradictory and require further study. In order to evaluate the impact of complex therapy with the inclusion of vitamin D on the clinical course and quality of life of patients with CHC combined with CP, 52 patients with CHC+CP were divided into 2 groups depending on the prescription scheme of the polyenzyme drug and vitamin D. It was established that as a result of prescribing complex therapy with the addition of vitamin D, 100% of patients in group 1 and only 82.1% of patients in group
2 achieved sustained virological response (SVR). After the treatment, a decrease in the frequency of complaints of diarrhea, constipation, flatulence, abdominal pain, itching, heaviness in the right hypochondrium, hepatomegaly, arthralgia and myalgia was found in all patients, with a significant predominance in the group that additionally received vitamin D. After treatment, patients in group 1 were less likely to be bothered by anxiety, increased fatigue, emotional lability, and significantly higher quality of life indicators were found than in patients in group 2. Therefore, the inclusion of a polyenzyme drug with minimal lipase activity of 25,000 and vitamin D in a dose of 4,000 IU/day to the complex treatment of patients with CHC combined with CP increases the efficacy of antiviral therapy and leads to a marked regression of manifestations of hepatobiliary dysfunction, asthenovegetative and dyspeptic syndromes, thereby reducing the situational anxiety and improves the quality of life of these patients.
popup.nrat_date
2026-06-13
